Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 4/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.49 |
| ▸ | KMT5A | Q9NQR1 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | ACP1 | P24666 | 2/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30125072 | 1.00 | ACKR3 (0.49) | ACKR3SLC2A1KMT5ACHRM2CHRM4 | |
| SCHEMBL20801391 | 0.83 | SLC2A1 (0.48) | ACKR3SLC2A1CHRM2CHRM4CHRM1 | |
| SCHEMBL8890898 | 0.81 | APP (0.58) | SLC2A1APPACP1TSHRALDH1A1 | |
| SCHEMBL30125103 | 0.81 | APP (0.58) | SLC2A1APPACP1TSHRALDH1A1 | |
| SCHEMBL9911789 | 0.81 | NSD2 (0.53) | ALDH1A1MEN1MAPTMAPK1KMT2A | |
| SCHEMBL12311274 | 0.79 | ACKR3 (0.56) | ACKR3CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL26911521 | 0.79 | GBA1 (0.46) | GBA1 | |
| SCHEMBL4089490 | 0.79 | TOP2A (0.63) | APPACP1TSHRALDH1A1CYP1A2 | |
| SCHEMBL23723356 | 0.78 | SLC2A1 (0.47) | ACKR3SLC2A1KMT5AAPPACHE | |
| SCHEMBL30125319 | 0.78 | SLC2A1 (0.47) | ACKR3SLC2A1KMT5AAPPACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | TroBio Therapeutics Pty Ltd (AU) | 2023-10-26 | — | — | US | disclosed |
| EP-4100395-A1 | QUINAZOLINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | Trobio Therapeutics Pty Ltd (AU) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021155426-A1 | QUINAZOLINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | TroBio Therapeutics Pty Ltd (AU) | 2021-08-12 | — | — | WO | disclosed |
| WO-1997020823-A2 | 2-AMINO QUINAZOLINE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 1997-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | NQO2, TP53, ABL1 | ACKR3 2898/4885SLC2A1 3899/4885KMT5A 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.